Phase 2 Asthma Trial, Recruiting NCT06932263 Sponsor: AstraZeneca Condition: Asthma
Back to Asthma

Phase 2 Asthma Trial, Recruiting

NCT06932263
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have signed and dated a written consent form before any study procedures begin.
  • Adults between 18 and 75 years of age at the time of signing the consent form.
  • People who have had a formal asthma diagnosis from a doctor for at least 12 months.
  • People who are currently taking medium or high dose inhaled corticosteroids (a type of preventer medication) together with a long-acting bronchodilator (a type of reliever medication).
  • People whose asthma is not well controlled, as measured by a standard asthma questionnaire score of 1.5 or higher (confirm with trial site).
  • People whose lung function test results fall within a specific range before using a bronchodilator (confirm with trial site).
  • People who have had at least 2 serious asthma attacks in the past 12 months, OR at least 1 serious asthma attack plus certain blood or breathing test results showing airway inflammation above a set level (confirm with trial site).
  • People who have completed an asthma daily diary with at least 70% compliance during the study lead-in period.
  • Women who could become pregnant must have a negative pregnancy test result.
  • All participants must use contraception in line with local guidelines for people taking part in clinical trials.

Who may not be able to join:

  • People who have finished a course of antibiotics for a respiratory infection within the 4 weeks before the first study visit.
  • People who have a significant lung or breathing condition other than asthma.
  • People who currently smoke, or former smokers who have a history of more than 10 pack-years of smoking (confirm with trial site).
  • People who have a significant heart valve condition called aortic stenosis or high blood pressure in the lungs (pulmonary arterial hypertension).
  • People who have active tuberculosis, hepatitis, HIV, a current cancer diagnosis, or a condition affecting the immune system.
  • People with unstable heart or cardiovascular conditions.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
26 March 2025
Est. completion
7 June 2027

Where this trial is recruiting

🇦🇷 Argentina 🇧🇷 Brazil 🇨🇱 Chile 🇨🇳 China 🇫🇷 France 🇬🇷 Greece 🇭🇺 Hungary 🇮🇳 India 🇮🇱 Israel 🇮🇹 Italy 🇯🇵 Japan 🇵🇪 Peru 🇵🇭 Philippines 🇿🇦 South Africa 🇰🇷 South Korea 🇪🇸 Spain 🇹🇼 Taiwan 🇹🇭 Thailand Turkey (Türkiye) 🇺🇸 United States 🇻🇳 Vietnam

Primary endpoints

Annualised rate of severe asthma exacerbations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov